Given the favorable outcome of T1a and T1b breast cancer, these small cancers were excluded from large clinical trials.18 Thus, the prognostic information was scare and the optimal treatment for small HER2‐enriched breast cancer remained undetermined. This evidence concerns the gene ERBB2 and cancer.